Identification and Characterization of the First Selective Y 4 Receptor Positive Allosteric Modulator
Mario Schubert, Jan Stichel, Yu Du, Iain R. Tough, Gregory Sliwoski, Jens Meiler, Helen M. Cox, C. David Weaver, Annette G. Beck‐Sickinger
Abstract
Mario Schubert, Jan Stichel, Yu Du, Iain R. Tough, Gregory Sliwoski, Jens Meiler, Helen M. Cox, C. David Weaver, Annette G. Beck‐Sickinger
Abstract
The human Y 4 receptor (Y 4 R) and its cognate ligand, pancreatic polypeptide (PP), are involved in the regulation of energy expenditure, satiety, and food intake. This system represents a potential target for the treatment of metabolic diseases and has been extensively investigated and validated in vivo. Here, we present the compound tBPC ( tert -butylphenoxycyclohexanol), a novel and selective Y 4 R positive allosteric modulator that potentiates Y 4 R activation in G-protein signaling and arrestin3 recruitment experiments. The compound has no effect on the binding of the orthosteric ligands, implying its allosteric mode of action at the Y 4 R and evidence for a purely efficacy-driven positive allosteric modulation. Finally, the ability of tBPC to selectively potentiate Y 4 R agonism initiated by PP was confirmed in mouse descending colon mucosa preparations expressing native Y 4 R, demonstrating Y 4 R positive allosteric modulation in vitro.
OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The human Y 4 receptor (Y 4 R) and its cognate ligand, pancreatic polypeptide (PP), are involved in the regulation of energy expenditure, satiety, and food intake. This system represents a potential target for the treatment of metabolic diseases and has been extensively investigated and validated in vivo. Here, we present the compound tBPC ( tert -butylphenoxycyclohexanol), a novel and selective Y 4 R positive allosteric modulator that potentiates Y 4 R activation in G-protein signaling and arrestin3 recruitment experiments. The compound has no effect on the binding of the orthosteric ligands, implying its allosteric mode of action at the Y 4 R and evidence for a purely efficacy-driven positive allosteric modulation. Finally, the ability of tBPC to selectively potentiate Y 4 R agonism initiated by PP was confirmed in mouse descending colon mucosa preparations expressing native Y 4 R, demonstrating Y 4 R positive allosteric modulation in vitro.
Key concepts: Allosteric regulation, Allosteric modulator, Chemistry, In vivo, Receptor, Structure–activity relationship, Ligand (biochemistry), Signal transduction